Jaguar Health Files 8-K on Financials
Ticker: JAGX · Form: 8-K · Filed: 2024-08-13T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Jaguar Health filed an 8-K on Aug 13th, standard financial update.
AI Summary
On August 13, 2024, Jaguar Health, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, along with financial statements and exhibits. No specific new financial figures or operational updates were detailed in the provided excerpt.
Why It Matters
This filing indicates Jaguar Health is providing updates on its financial condition and operational results to the SEC, which is standard practice for public companies.
Risk Assessment
Risk Level: low — This is a routine SEC filing for financial reporting and does not contain new material information or significant risk factors.
Key Players & Entities
- Jaguar Health, Inc. (company) — Registrant
- August 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 200 Pine Street , Suite 400 San Francisco , California 94104 (address) — Address of principal executive offices
- 415-371-8300 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Jaguar Health, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, along with submitting Financial Statements and Exhibits.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on August 13, 2024.
In which state was Jaguar Health, Inc. incorporated?
Jaguar Health, Inc. was incorporated in Delaware.
What is the principal executive office address for Jaguar Health, Inc.?
The principal executive office address is 200 Pine Street, Suite 400, San Francisco, California 94104.
What is the telephone number for Jaguar Health, Inc.?
The telephone number for Jaguar Health, Inc. is (415) 371-8300.
Filing Stats: 502 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-13 08:13:39
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share JAGX The Nasdaq Capital Mar
Filing Documents
- tm2421533d1_8k.htm (8-K) — 26KB
- tm2421533d1_ex99-1.htm (EX-99.1) — 67KB
- tm2421533d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-088683.txt ( ) — 280KB
- jagx-20240813.xsd (EX-101.SCH) — 3KB
- jagx-20240813_lab.xml (EX-101.LAB) — 33KB
- jagx-20240813_pre.xml (EX-101.PRE) — 22KB
- tm2421533d1_8k_htm.xml (XML) — 4KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Conditions. On August 13, 2024, Jaguar Health, Inc. (the "Company") issued a press release announcing second quarter 2024 results. A copy of this press release is furnished as Exhibit 99.1 to this report. The information in Item 2.02 and the press release furnished as Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, or incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 13, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAGUAR HEALTH, INC. By: /s/ Lisa A. Conte Name: Lisa A. Conte Title: President and Chief Executive Officer Date: August 13, 2024